Clinically relevant drug interactions between anticancer drugs and psychotropic agents

European Journal of Cancer Care

Volumn 20, Issue 1, 2011, Pages 6-32

  Yap, K Y L ^a   Tay, W L ^a   Chui, W K ^a   Chan, A ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Anticancer drugs; Chemotherapy; Clinically relevant; Drug interactions; Psychotropic drugs

Indexed keywords

EID: 84983721633     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2009.01113.x     Document Type: Review

References (167)

1. Abernethy D.R., Greenblatt D.J. & Shader R.I. (1984) Imipramine disposition in users of oral contraceptive steroids. Clinical Pharmacology and Therapeutics 35, 792-797.
2. Abramowicz M., Rizack M.A., Goodstein D., Faucard A., Hansten P.D., Steigbigel N.H., Mukherjee S.K., Smoller J.W., Zuccotti G. & Aschenbrenner M. (1997) Quetiapine for schizophrenia. Medical Letter on Drugs and Therapeutics 39, 117-118.
3. ® (paclitaxel protein-bound particles) for injectable suspension. [product information], Los Angeles, CA.
4. Akizuki N., Akechi T., Nakanishi T., Yoshikawa E., Okamura M., Nakano T., Murakami Y. & Uchitomi Y. (2003) Development of a brief screening interview for adjustment disorders and major depression in patients with cancer. Cancer 97, 2605-2613.
5. ® (filgrastim) injection. [product information], Thousands Oaks, CA.
6. ® (pegfilgrastim). [product information], Thousand Oaks, CA.
7. Anderson G.D. (1998) A mechanistic approach to antiepileptic drug interactions. Annals of Pharmacotherapy 32, 554-563.
8. Argov Z. & Mastaglia F.L. (1979) Drug-induced peripheral neuropathies. British Medical Journal 1, 663-666.
9. Ariffin H., Omar K.Z., Ang E.L. & Shekhar K. (2003) Severe vincristine neurotoxicity with concomitant use of itraconazole. Journal of Paediatrics and Child Health 39, 638-639.
10. ® (tamoxifen citrate) tablets. [product information], Wilmington, DE.
11. ® (gefitinib) tablets. [product information], Wilmington, DE.
12. ® (quetiapine fumarate) tablets. [product information], Wilmington, DE.
13. ® (docetaxel) injection concentrate. [product information], Bridgewater, NJ.
14. Bailey R.K., Geyen D.J., Scott-Gurnell K., Hipolito M.M., Bailey T.A. & Beal J.M. (2005) Understanding and treating depression among cancer patients. International Journal of Gynecological Cancer 15, 203-208.
15. Barr Laboratories (2003) Naltrexone hydrochloride tablets. [product information], Pomona, NY.
16. Baumann P. & Rochat B. (1995) Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. International Clinical Psychopharmacology 10, 15-21.
17. Baxter Healthcare Corporation (2006) Midazolam hydrochloride injection. [product information], Caguas, Puerto Rico.
18. ® (sorafenib) tablets. [product information], West Haven, CT.
19. Bedford Laboratories (2001) Vinblastine sulfate for injection USP. [product information], Bedford, OH.
20. Beijnen J.H., Vlasveld L.T., Wanders J., Ten Bokkel Huinink W.W. & Rodenhuis S. (1992) Effect of cisplatin-containing chemotherapy on lithium serum concentrations. Annals of Pharmacotherapy 26, 488-490.
21. Beijnen J.H., Bais E.M. & Ten Bokkel Huinink W.W. (1994) Lithium pharmacokinetics during cisplatin-based chemotherapy: a case report. Cancer Chemotherapy and Pharmacology 33, 523-526.
22. Belle D.J., Ernest C.S., Sauer J.-M., Smith B.P., Thomasson H.R. & Witcher J.W. (2002) Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. Journal of Clinical Pharmacology 42, 1219-1227.
23. Bergstrom R.F., Goldberg M.J., Cerimele B.J. & Hatcher B.L. (1997) Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clinical Pharmacology and Therapeutics 62, 643-651.
24. Bermúdez M., Fuster J.L., Llinares E., Galera A. & Gonzalez C. (2005) Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. Journal of Pediatric Hematology/Oncology 27, 389-392.
25. Borges S., Desta Z., Li L., Skaar T.C., Ward B.A., Nguyen A., Jin Y., Storniolo A.M., Nikoloff D.M., Wu L., Hillman G., Hayes D.F., Stearns V. & Flockhart D.A. (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clinical Pharmacology and Therapeutics 80, 61-74.
26. ® (paclitaxel) injection. [product information], Princeton, NJ.
27. British Medical Association & Pharmaceutical Society of Great Britain (2007) British National Formulary, 53rd edn. BMJ Publishing Group & RPS Publishing, London, UK.
28. Buclin T., Mazzocato C., Berney A. & Stiefel F. (2001) Psychopharmacology in supportive care of cancer: a review for the clinician. IV. Other psychotropic agents. Supportive Care in Cancer 9, 213-222.
29. Calvert H., Twelves C., Ranson M., Anthoney A., Plummer R., Fettner S., Dayaram B., Lum B., Hamilton M. & Rakhit A. (2005) The effect of erlotinib on CYP3A4 activity, as quantified by the erythromycin breath test and oral midazolam kinetics in cancer patients: preliminary results. Journal of Clinical Oncology 23, 3076.
30. ® (thalidomide) capsules. [product information], Summit, NJ.
31. Chan J.D. (1998) Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy 18, 1304-1307.
32. Clark D.B., Andrus M.R. & Byrd D.C. (2006) Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. Pharmacotherapy 26, 269-276.
33. Clarke Institute of Psychiatry (2007) Clinical Handbook of Psychotropic Drugs, 17th edn. Hogrefe and Huber Publishers, Toronto, Canada.
34. Coplan J.D. & Gorman J.M. (1993) Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. American Journal of Psychiatry 150, 837.
35. Cresteil T., Monsarrat B., Alvinerie P., Treluyer J.M., Vieira I. & Wright M. (1994) Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Research 54, 386-392.
36. Crouch M.A., Limon L. & Cassano A.T. (2003) Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 23, 881-908.
37. Damkier P., Hansen L.L. & Brøsen K. (1999) Effect of fluvoxamine on the pharmacokinetics of quinidine. European Journal of Clinical Pharmacology 55, 451-456.
38. D'Arcy P.F. & Griffin J.P. (1995) Interactions with drugs used in the treatment of depressive illness. Adverse Drug Reactions and Toxicological Reviews 14, 211-231.
39. De Ponti F., Poluzzi E. & Montanaro N. (2000) QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. European Journal of Clinical Pharmacology 56, 1-18.
40. De Ponti F., Poluzzi E., Vaccheri A., Bergman U., Bjerrum L., Ferguson J., Frenz K.J., McManus P., Schubert I., Selke G., Terzis-Vaslamatzis G. & Montanaro N. (2002) Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries. British Journal of Clinical Pharmacology 54, 171-177.
41. Desai P.B., Duan J.Z., Zhu Y.W. & Kouzi S. (1998) Human liver microsomal metabolism of paclitaxel and drug interactions. European Journal of Drug Metabolism and Pharmacokinetics 23, 417-424.
42. DeVane C.L., Donovan J.L., Liston H.L., Markowitz J.S., Cheng K.T., Risch S.C. & Willard L. (2004) Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. Journal of Clinical Psychopharmacology 24, 4-10.
43. Domino E.F., Sullivan T.S. & Luby E.D. (1962) Barbiturate intoxication in a patient treated with a MAO inhibitor. American Journal of Psychiatry 118, 941-943.
44. Drugsite Trust (2000) Drugs.com™: drug interactions checker. Available at: (Accessed 31 October 2008).
45. Edelbroek P.M., Zitman F.G., Knoppert-van der Klein E.A., van Putten P.M. & de Wolff F.A. (1987) Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women. Clinica Chimica Acta 165, 177-187.
46. ® (pemetrexed) for injection. [product information], Indianapolis, IN.
47. ® (atomoxetine hydrochloride) capsules. [product information], Indianapolis, IN.
48. ® (fluoxetine hydrochloride) capsules. [product information], Indianapolis, IN.
49. Eriksson T., Björkman S. & Höglund P. (2001) Clinical pharmacology of thalidomide. European Journal of Clinical Pharmacology 57, 365-376.
50. Feighner J.P., Boyer W.F., Tyler D.L. & Neborsky R.J. (1990) Adverse consequences of fluoxetine-MAOI combination therapy. Journal of Clinical Psychiatry 51, 222-225.
51. Fleishaker J.C. & Hulst L.K. (1994) A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. European Journal of Clinical Pharmacology 46, 35-39.
52. ® (escitalopram oxalate) tablets and solution. [product information], St. Louis, MO.
53. Fujita K., Ando Y., Narabayashi M., Miya T., Nagashima F., Yamamoto W., Kodama K., Araki K., Endo H. & Sasaki Y. (2005) Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecan. Drug Metabolism and Disposition 33, 1785-1790.
54. Gardner-Thorpe C. & Benjamin S. (1971) Peripheral neuropathy after disulfiram administration. Journal of Neurology, Neurosurgery, and Psychiatry 34, 253-259.
55. Gillies J., Hung K.A., Fitzsimons E. & Soutar R. (1998) Severe vincristine toxicity in combination with itraconazole. Clinical and Laboratory Haematology 20, 123-124.
56. Glassman A.H. & Bigger J.T., Jr. (2001) Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. American Journal of Psychiatry 158, 1774-1782.
57. ® (bupropion hydrochloride) tablets. [product information], Research Triangle Park, NC.
58. Goulet K. & Grignon S. (2008) Case report: clozapine given in the context of chemotherapy for lung cancer. Psycho-oncology 17, 512-516.
59. Graber M.A., Hoehns T.B. & Perry P.J. (1994) Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. Annals of Pharmacotherapy 28, 732-735.
60. Greenblatt D.J., Preskorn S.H., Cotreau M.M., Horst W.D. & Harmatz J.S. (1992) Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clinical Pharmacology and Therapeutics 52, 479-486.
61. Greenblatt D.J., von Moltke L.L., Harmatz J.S., Mertzanis P., Graf J.A., Durol A.L.B., Counihan M., Roth-Schechter B. & Shader R.I. (1998) Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clinical Pharmacology and Therapeutics 64, 661-671.
62. Grimsley S.R., Jann M.W., Carter J.G., D'Mello A.P. & D'Souza M.J. (1991) Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clinical Pharmacology and Therapeutics 50, 10-15.
63. ® (toremifene citrate) tablets. [product information], Memphis, TN.
64. Hanioka N., Ozawa S., Jinno H., Tanaka-Kagawa T., Nishimura T., Ando M. & Sawada Ji J. (2002) Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Drug Metabolism and Disposition 30, 391-396.
65. Hatta K., Takahashi T., Nakamura H., Yamashiro H., Asukai N., Matsuzaki I. & Yonezawa Y. (2001) The association between intravenous haloperidol and prolonged QT interval. Journal of Clinical Psychopharmacology 21, 257-261.
66. Haymän M. & Wilkins P.A. (1956) Polyneuropathy as a complication of disulfiram therapy of alcoholism. Quarterly Journal of Studies on Alcohol 17, 601-607.
67. Hemeryck A. & Belpaire F.M. (2002) Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Current Drug Metabolism 3, 13-37.
68. Hodgman M.J., Martin T.G. & Krenzelok E.P. (1997) Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Human and Experimental Toxicology 16, 14-17.
69. Ito D., Amano T., Sato H. & Fukuuchi Y. (2001) Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease. Journal of Neurology 248, 533-534.
70. Jeng M.R. & Feusner J. (2001) Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia. Pediatric Hematology and Oncology 18, 137-142.
71. Jin Y., Desta Z., Stearns V., Ward B., Ho H., Lee K.-H., Skaar T., Storniolo A.M., Li L., Araba A., Blanchard R., Nguyen A., Ullmer L., Hayden J., Lemler S., Weinshilboum R.M., Rae J.M., Hayes D.F. & Flockhart D.A. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. Journal of the National Cancer Institute 97, 30-39.
72. Kamaluddin M., McNally P., Breatnach F., O'Marcaigh A., Webb D., O'Dell E., Scanlon P., Butler K. & O'Meara A. (2001) Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatrica 90, 1204-1207.
73. Karas S., Jr. (1981) The potential for drug interactions. Annals of Emergency Medicine 10, 627-630.
74. Kashuba A.D.M., Nafziger A.N., Kearns G.L., Leeder J.S., Gotschall R., Rocci M.L.J., Kulawy R.W., Beck D.J. & Bertino J.S., Jr. (1998) Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clinical Pharmacology and Therapeutics 64, 257-268.
75. Khurana R.C. (1972) Estrogen-imipramine interaction. Journal of the American Medical Association 222, 702-703.
76. Klein T.E., Chang J.T., Cho M.K., Easton K.L., Fergerson R., Hewett M., Lin Z., Liu Y., Liu S., Oliver D.E., Rubin D.L., Shafa F., Stuart J.M. & Altman R.B. (2001) Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenomics Journal 1, 167-170.
77. Krishnan K.R., France R.D. & Ellinwood E.H., Jr. (1984) Tricyclic-induced akathisia in patients taking conjugated estrogens. American Journal of Psychiatry 141, 696-697.
78. Kuhn W.L. & Van Maanen E.F. (1961) Central nervous system effects of thalidomide. Journal of Pharmacology and Experimental Therapeutics 134, 60-68.
79. Kumar G.N., Walle U.K. & Walle T. (1994) Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. Journal of Pharmacology and Experimental Therapeutics 268, 1160-1165.
80. Lacy C.F., Armstrong L.L., Goldman M.P. & Lance L.L. (20072008) Drug Information Handbook with International Trade Names Index, 15th edn. Lexi-comp, Hudson, OH, USA.
81. Lappin R.I. & Auchincloss E.L. (1994) Treatment of the serotonin syndrome with cyproheptadine. New England Journal of Medicine 331, 1021-1022.
82. Lefebvre H., Noblet C., Moore N. & Wolf L.M. (1995) Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline. Clinical Endocrinology 42, 95-98.
83. Lehmann D., Nelsen J., Ramanath V., Newman N., Duggan D. & Smith A. (2004) Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition. Journal of Clinical Pharmacology 44, 861-865.
84. Li J., Zhao M., He P., Hidalgo M. & Baker S.D. (2007) Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clinical Cancer Research 13, 3731-3737.
85. Lissoni P., Malugani F., Bordin V., Conti A., Maestroni G. & Tancini G. (2002) A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone. Neuroendocrinology Letters 23, 255-258.
86. McGrath P.J., Steward J.W. & Quitkin F.M. (1989) A possible L-deprenyl induced hypertensive reaction. Journal of Clinical Psychopharmacology 9, 310-311.
87. Markowitz J.S. & Patrick K.S. (2001) Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clinical Pharmacokinetics 40, 753-772.
88. Marre F., Sanderink G.J., de Sousa G., Gaillard C., Martinet M. & Rahmani R. (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Research 56, 1296-1302.
89. Massoud M., Armand J.P. & Ribrag V. (2004) Procarbazine in haematology: an old drug with a new life? European Journal of Cancer 40, 1924-1927.
90. Mayne Pharma (USA) (2004) Vinorelbine tartrate injection solution. [product information], Paramus, NJ.
91. ® (dexamethasone tablets USP). [product information], Whitehouse Station, NJ.
92. Miceli J.J., Anziano R.J., Robarge L., Hansen R.A. & Laurent A. (2000a) The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. British Journal of Clinical Pharmacology 49, 65S-70S.
93. Miceli J.J., Smith M., Robarge L., Morse T. & Laurent A. (2000b) The effects of ketoconazole on ziprasidone pharmacokinetics - a placebo-controlled crossover study in healthy volunteers. British Journal of Clinical Pharmacology 49, 71S-76S.
94. Miovic M. & Block S. (2007) Psychiatric disorders in advanced cancer. Cancer 110, 1665-1676.
95. Moddel G., Bilbao J.M., Payne D. & Ashby P. (1978) Disulfiram neuropathy. Archives of Neurology 35, 658-660.
96. Mylan Pharmaceuticals (2006) Bromocriptine mesylate tablet and capsule. [product information], Morgantown, WV.
97. Nakajima M., Suzuki T., Sasaki T., Yokoi T., Hosoyamada A., Yamamoto T. & Kuroiwa Y. (1999) Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. Therapeutic Drug Monitoring 21, 507-513.
98. Neuvonen P.J., Pohjola-Sintonen S., Tacke U. & Vuori E. (1993) Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 342, 1419.
99. Novartis Pharmaceuticals Corporation (2001 & 2005) Gleevec™ (imatinib mesylate) capsules. [product information], East Hanover, NJ.
100. ® (clozapine) tablets. [product information], East Hanover, NJ.
101. ® (methylphenidate hydrochloride) tablets. [product information], East Hanover, NJ.
102. ® (mirtazapine) tablets. [product information], Roseland, NJ.
103. ® (aripiprazole) tablets and oral solution. [product information], Princeton, NJ.
104. Peng B., Lloyd P. & Schran H. (2005) Clinical pharmacokinetics of imatinib. Clinical Pharmacokinetics 44, 879-894.
105. Peterson L.G., Leipman M. & Bongar B. (1987) Psychotropic medications in patients with cancer. General Hospital Psychiatry 9, 313-323.
106. ® (donepezil hydrochloride) tablet. [product information], New York, NY.
107. ® (irinotecan hydrochloride) injection. [product information], New York, NY.
108. Pichard L., Fabre I., Daujat M., Domergue J., Joyeux H. & Maurel P. (1992) Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Molecular Pharmacology 41, 1047-1055.
109. Pietruszka L.J., Biermann W.A. & Vlasses P.H. (1985) Evaluation of cisplatin-lithium interaction. Drug Intelligence and Clinical Pharmacy 19, 31-32.
110. Poster D.S. (1978) Procarbazine-prochlorperazine interaction: an underreported phenomenon. Journal of Medicine 9, 519-524.
111. Prakash C., Kamel A., Cui D., Whalen R.D., Miceli J.J. & Tweedie D. (2000) Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. British Journal of Clinical Pharmacology 49, 35S-42S.
112. Richards S., Umbreit J.N., Fanucchi M.P., Giblin J. & Khuri F. (2003) Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan. Southern Medical Journal 96, 1031-1033.
113. Richter T., Mürdter T.E., Heinkele G., Pleiss J., Tatzel S., Schwab M., Eichelbaum M. & Zanger U.M. (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. Journal of Pharmacology and Experimental Therapeutics 308, 189-197.
114. Riechelmann R.P. & Saad E.D. (2006) A systematic review on drug interactions in oncology. Cancer Investigation 24, 704-712.
115. Riechelmann R.P., Tannock I.F., Wang L., Saad E.D., Taback N.A. & Krzyzanowska M.K. (2007) Potential drug interactions and duplicate prescriptions among cancer patients. Journal of the National Cancer Institute 99, 592-600.
116. Rivory L.P. (2000) Metabolism of CPT-11: impact on activity. Annals of the New York Academy of Sciences 922, 205-215.
117. ®-A (interferon alfa-2a, recombinant). [product information], Nutley, NJ.
118. ® (ziprasidone hydrochloride). [product information], New York, NY.
119. ® (sertraline hydrochloride) tablets. [product information], New York, NY.
120. Rojas-Fernandez C., Fisher C. & Carrier L. (2000) Drug interactions and donepezil. Journal of the American Geriatrics Society 48, 597-598.
121. Roxane Laboratories (2005) Lithium carbonate extended release tablet. [product information].
122. Sandoz (2007) Fluvoxamine maleate tablet. [product information], Princeton, NJ.
123. Sanofi-Aventis (2004) Eloxatin™ (oxaliplatin) for injection. [product information], New York, NY.
124. Sathiapalan R.K. & El-Solh H. (2001) Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature. Pediatric Hematology and Oncology 18, 543-546.
125. Sathiapalan R.K., Al-Nasser A., El-Solh H., Al-Mohsen I. & Al-Jumaah S. (2002) Vincristine-itraconazole interaction: cause for increasing concern. Journal of Pediatric Hematology/Oncology 24, 591.
126. ® A (interferon alfa-2b, recombinant for injection). [product information], Kenilworth, NJ.
127. Schuckit M., Robins E. & Feighner J. (1971) Tricyclic antidepressants and monoamine oxidase inhibitors. Archives of General Psychiatry 24, 509-514.
128. Schulz R., Antonin K.-H., Hoffmann E., Jedrychowski M., Nilsson E., Schick C. & Bieck P.R. (1989) Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clinical Pharmacology and Therapeutics 46, 528-536.
129. Sherman M., Hauser G.C. & Glover B.H. (1964) Toxic reactions to tranylcypromine. American Journal of Psychiatry 120, 1019-1021.
130. Shou M., Grogan J., Mancewicz J.A., Krausz K.W., Gonzalez F.J., Gelboin H.V. & Korzekwa K.R. (1994) Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33, 6450-6455.
131. ® (vincristine sulfate injection USP). [product information], Irvine, CA.
132. ® (procarbazine hydrochloride) capsules. [product information], Gaithersburg, MD.
133. Sjöqvist F. (1965) Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances. Proceedings of the Royal Society of Medicine 58, 967-978.
134. Solimando D.A.J. (2007) Drug Information Handbook for Oncology, 6th edn. Lexi-comp, Hudson, OH, USA.
135. Somani S.M. & Khurana R.C. (1973) Mechanism of estrogen-imipramine interaction. Journal of the American Medical Association 223, 560.
136. ® (selegiline) patch. [product information], Tampa. FL.
137. Spencer C.M. & Faulds D. (1994) Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 48, 794-847.
138. Stearns V., Johnson M.D., Rae J.M., Morocho A., Novielli A., Bhargava P., Hayes D.F., Desta Z. & Flockhart D.A. (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Journal of the National Cancer Institute 95, 1758-1764.
139. Stedman T.L. (2005) Stedman's Medical Dictionary, 28th edn. Lippincott Williams & Wilkins, Baltimore, MD, USA.
140. Sternbach H. (1991) The serotonin syndrome. American Journal of Psychiatry 148, 705-713.
141. Stiefel F., Berney A. & Mazzocato C. (1999) Psychopharmacology in supportive care in cancer: a review for the clinician. I. Benzodiazepines. Supportive Care in Cancer 7, 379-385.
142. Stiefel F.C., Kornblith A.B. & Holland J.C. (1990) Changes in the prescription patterns of psychotropic drugs for cancer patients during a 10-year period. Cancer 65, 1048-1053.
143. Stockley I.H. (1999) Drug interactions, 5th edn. Pharmaceutical Press, London, UK.
144. Swaisland H.C., Ranson M., Smith R.P., Leadbetter J., Laight A., McKillop D. & Wild M.J. (2005) Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clinical Pharmacokinetics 44, 1067-1081.
145. Sweetman S.C. (2002) Martindale: The Complete Drug Reference, 33rd edn. Pharmaceutical Press, London, UK.
146. Takahashi N., Kameoka Y., Yamanaka Y., Ubukawa K., Saito K., Fujishima M., Fujishima N., Saito H., Hirokawa M., Scott S.A. & Sawada K. (2008) Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma. Internal Medicine (Tokyo, Japan) 47, 651-653.
147. Tamargo J. (2000) Drug-induced torsade de pointes: from molecular biology to bedside. Japanese Journal of Pharmacology 83, 1-19.
148. Thami G.P., Kaur S. & Kanwar A.J. (2002) Delayed reactivation of haloperidol induced photosensitive dermatitis by methotrexate. Postgraduate Medical Journal 78, 116-117.
149. Tiseo P.J., Perdomo C.A. & Friedhoff L.T. (1998) Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. British Journal of Clinical Pharmacology 46, 30-34.
150. Tobe S.W., Siu L.L., Jamal S.A., Skorecki K.L., Murphy G.F. & Warner E. (1995) Vinblastine and erythromycin: an unrecognized serious drug interaction. Cancer Chemotherapy and Pharmacology 35, 188-190.
151. Towbin J.A. & Vatta M. (2001) Molecular biology and the prolonged QT syndromes. American Journal of Medicine 110, 385-398.
152. Turpeinen M., Tolonen A., Uusitalo J., Jalonen J., Pelkonen O. & Laine K. (2005) Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clinical Pharmacology and Therapeutics 77, 553-559.
153. Ueng Y.-F., Kuwabara T., Chun Y.-J. & Guengerich F.P. (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36, 370-381.
154. Vandel P., Bonin B., Leveque E., Sechter D. & Bizouard P. (1997) Tricyclic antidepressant-induced extrapyramidal side effects. European Neuropsychopharmacology 7, 207-212.
155. Vieweg W.V.R. (2003) New generation antipsychotic drugs and QTc interval prolongation. Primary Care Companion to the Journal of Clinical Psychiatry 5, 205-215.
156. Vieweg W.V.R., Schneider R.K. & Wood M.A. (2005) Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine. Acta Psychiatrica Scandinavica 112, 318-322.
157. Villikka K., Kivistö K.T. & Neuvonen P.J. (1998) The effect of dexamethasone on the pharmacokinetics of triazolam. Pharmacology and Toxicology 83, 135-138.
158. White K. & Simpson G. (1984) The combined use of MAOIs and tricyclics. Journal of Clinical Psychiatry 45, 67-69.
159. Wilner K.D., Hansen R.A., Folger C.J. & Geoffroy P. (2000) The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. British Journal of Clinical Pharmacology 49, 57S-60S.
160. Wishart D.S., Knox C., Guo A.C., Shrivastava S., Hassanali M., Stothard P., Chang Z. & Woolsey J. (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Research 34, D668-D672.
161. Witchel H.J., Hancox J.C. & Nutt D.J. (2003) Psychotropic drugs, cardiac arrhythmia, and sudden death. Journal of Clinical Psychopharmacology 23, 58-77.
162. Wong Y.W.J., Yeh C. & Thyrum P.T. (2001) The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. Journal of Clinical Psychopharmacology 21, 89-93.
163. Wooldridge J.E., Anderson C.M. & Perry M.C. (2001) Corticosteroids in advanced cancer. Oncology (Williston Park) 15, 225-236.
164. Yap K.Y.-L., Chui W.K. & Chan A. (2008) Drug interactions between chemotherapeutic regimens and antiepileptics. Clinical Therapeutics 30, 1385-1407.
165. Zabora J., BrintzenhofeSzoc K., Curbow B., Hooker C. & Piantadosi S. (2001) The prevalence of psychological distress by cancer site. Psycho-oncology 10, 19-28.
166. Zhou S.-F. (2008) Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Current Drug Metabolism 9, 310-322.
167. Zhou-Pan X.R., Seree E., Zhou X.J., Placidi M., Maurel P., Barra Y. & Rahmani R. (1993) Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Research 53, 5121-5126.